Anti-Claudin-1 Conjugated to a Near-Infrared Fluorophore Targets Colon Cancer in PDOX Mouse Models.
Animals
Antibodies, Monoclonal
/ administration & dosage
Benzenesulfonates
/ administration & dosage
Cell Line, Tumor
Claudin-1
/ immunology
Colon
/ diagnostic imaging
Colonic Neoplasms
/ diagnostic imaging
Dose-Response Relationship, Drug
Fluorescent Dyes
/ administration & dosage
Humans
Immunoconjugates
/ administration & dosage
Indoles
/ administration & dosage
Injections, Intravenous
Male
Mice
Mice, Nude
Peritoneal Neoplasms
/ diagnostic imaging
Spectroscopy, Near-Infrared
/ methods
Surgery, Computer-Assisted
/ methods
Xenograft Model Antitumor Assays
Claudin
Colon cancer
Fluorescence guided surgery
IRDye800CW
Near infrared dye
Journal
The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
28
02
2019
revised:
23
03
2019
accepted:
10
04
2019
pubmed:
12
5
2019
medline:
31
1
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
Claudins are tight-junction proteins, which maintain an epithelial barrier in normal colon cells. Overexpression of Claudin-1 has been implicated for development of colon cancer. We postulated that Claudin-1 may be a useful target in near-infrared imaging and fluorescence-guided surgery. We conjugated Claudin-1 antibody to LI-COR IR800DyeCW (Claudin-1-IRDye800CW). Western blotting of 9 human colon cancer cell lysates was performed. Animal imaging was performed with the LI-COR Pearl Trilogy Fluorescence Imaging System. A dose-response study was carried out with subcutaneous LS174T colon cancer cell line models. Increasing doses of Claudin-1-IRDye800CW via tail vein injection were administered to three groups of mice. Two groups of mice were used as controls (antibody alone, and dye alone). In vivo imaging was performed at 24, 48, and 72 h after administration of the conjugated dye. Orthotopic implantation of patient-derived tumors and cell lines was performed and peritoneal carcinomatosis models were created. After tumor growth, mice were administered Claudin-1-IRDye800CW and imaged in vivo 48 h later. The mice were euthanized and laparotomy was performed to assess internal organs and toxicity. Western blotting revealed that all colon cancer cell lysates expressed varying amounts of Claudin-1. All tumors demonstrated strong and specific fluorescence labeling at 800 nm, even with the lowest dose of 12.5 μg of Claudin-1-IRDye800CW. Claudin-1 is a useful target for near-infrared antibody-based imaging for visualization of colorectal tumors for future use in fluorescence-guided surgery.
Identifiants
pubmed: 31077946
pii: S0022-4804(19)30234-3
doi: 10.1016/j.jss.2019.04.048
pmc: PMC7144806
mid: NIHMS1575245
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Benzenesulfonates
0
CLDN1 protein, human
0
Claudin-1
0
Fluorescent Dyes
0
IRDye 800CW
0
Immunoconjugates
0
Indoles
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-150Subventions
Organisme : BLRD VA
ID : I01 BX002086
Pays : United States
Organisme : BLRD VA
ID : I01 BX003856
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA216746
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA121938
Pays : United States
Informations de copyright
Published by Elsevier Inc.
Références
Nat Rev Cancer. 2015 Aug;15(8):451-2
pubmed: 26422835
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Invest. 2005 Jul;115(7):1765-76
pubmed: 15965503
Sci Rep. 2018 Apr 9;8(1):5686
pubmed: 29632347
Cell Mol Gastroenterol Hepatol. 2015 Dec 13;2(2):222-237
pubmed: 27840845
Pflugers Arch. 2017 Jan;469(1):69-75
pubmed: 27988840
Oncotarget. 2018 Dec 18;9(99):37333-37342
pubmed: 30647873
Gastroenterology. 2011 Dec;141(6):2140-53
pubmed: 21878201
Ann Surg. 2017 Jul;266(1):36-47
pubmed: 28045715
PLoS One. 2015 Mar 23;10(3):e0121989
pubmed: 25799218
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):181-191
pubmed: 29361435
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1469-74
pubmed: 25893411
Gut. 2014 Apr;63(4):622-34
pubmed: 23766441
Mol Cancer. 2014 Jul 06;13:167
pubmed: 24997475
J Nucl Med. 2019 Jun;60(6):758-763
pubmed: 30733319